Regeneron Pharmaceuticals Inc
Most Recent
Trump Pushes Regeneron and Eli Lilly Antibodies for COVID-19, Stocks Up
Regeneron to Partner With Roche on COVID-19 Drug
Regeneron Is Down despite Earnings Beat
Regeneron (REGN) reported its Q2 earnings results before the markets opened. REGN reported revenues of $1.93 billion, a YoY increase of 20%.
Sanofi’s Immunology Portfolio in the First Quarter
In the first quarter, Sanofi’s (SNY) Immunology Franchise reported net sales of 359 million euros.
Analyzing Sanofi’s Oncology Portfolio in the First Quarter
In the first quarter, Sanofi’s (SNY) Oncology franchise reported net sales of 399 million euros, a YoY rise of 7.8% on a CER (constant exchange rate) basis.
Analysts Raise Their Target Price for Regeneron in March
Wall Street analysts expect a potential upside of 6.79% for Regeneron Pharmaceuticals based on the company’s closing price on March 27.
What Are Teva Pharmaceutical’s Key Growth Drivers in 2019?
On its fourth-quarter earnings conference call, Teva Pharmaceutical (TEVA) highlighted Ajovy and Austedo as its key growth drivers for 2019.
Understanding Sarepta Therapeutics’ Operational Performance
Sarepta Therapeutics’ (SRPT) R&D (research and development) expenses rose YoY (year-over-year) to $86.58 million.
Taking Stock of bluebird bio’s Performance
In the third quarter, bluebird bio’s total revenue rose YoY (year-over-year) to $11.53 million from $7.71 million.
Do Analysts See Any Upside for Regeneron Stock?
Of the 26 analysts covering Regeneron Pharmaceuticals (REGN), eight recommend “buy” or a higher rating, 17 recommend “hold,” and one recommends “sell.”
Regeneron Pharmaceuticals’ Gross Margin Trends
In fiscal 2018 and fiscal 2019, Regeneron Pharmaceuticals (REGN) is expected to generate revenue of $6.49 billion and $7.16 billion, respectively, compared with revenue of $5.87 billion in fiscal 2017.
Austedo Is on Solid Growth Trajectory in 2018
In the third quarter, Austedo reported revenues of $62 million, which is a YoY rise of 933.33% and a sequential rise of 40.91%.
Jazz Pharmaceuticals: Analysts’ View in November
On November 12, Jazz Pharmaceuticals’ stock price closed at $148.54, which represents ~2.04% growth from the close of $145.57 on November 9.
Alkermes in the Third Quarter: A Performance Overview
Alkermes (ALKS) reported its third-quarter results on October 23. It generated net revenues of $248.7 million, a 14% YoY growth.
Amgen: Analysts’ Recommendations on October 25
Wall Street analysts expect Amgen’s (AMGN) revenues to decrease marginally by ~0.1% to $5.769 billion during the third quarter.
Biogen Surpassed Estimates in Q3 2018, Reports Strong Growth
Today, Biogen (BIIB) reported EPS of $7.40 on revenues of ~$3.44 billion. BIIB beat the EPS estimate of $6.78 on revenues of ~$3.33 billion.
Regeneron and Alnylam Collaborate for NASH Research Program
Alnylam Pharmaceuticals (ALNY) is currently trading 1.47% higher than its 52-week low price of $78.85 and 48.04% lower than its 52-week high price of $153.99.
How Regeneron Stock Performed in the First Half of October
On October 15, Regeneron (REGN) closed at $377.55, which was 1.72% lower than its previous closing price on October 12.
Biogen: Revenue Growth Is Expected in Q3
Interferon contributed ~18% of Biogen’s total revenues. Analysts expect the revenues to decrease during the third quarter.
Amgen’s Repatha and Blincyto: How They Did in 3Q17
In 4Q17, Amgen’s (AMGN) Repatha generated revenues of $98 million, which reflected a 69% growth YoY (year-over-year) and a 10% growth quarter-over-quarter.
Ionis Pharmaceuticals’ Valuations on September 28
Ionis reported revenues of $118.0 million during the second quarter for 5.0% growth in year-over-year revenues compared to the second quarter of 2017.
Ionis Pharmaceuticals’ Stock Performance in September
On September 28, Ionis Pharmaceuticals received one “strong buy” rating, three “buy” ratings, seven “hold” ratings, and two “sell” ratings.
Sanofi’s Dupixent: Growth Prospects and Phase 3 Trials
Sanofi and Regeneron are conducting clinical studies for the treatment of a range of type 2 inflammation conditions with Dupixent.
Sanofi Eyes Market Expansion with Phase 3 Data for Dupixent
On September 15, Sanofi and Regeneron announced Phase 3 data results for Dupixent for the treatment of moderate-to-severe atopic dermatitis.
Shire’s Quarterly Revenue Trend
Biotechnology company Shire (SHPG) reported a 4.6% YoY (year-over-year) rise in revenue to ~$3.9 billion in the second quarter.
Analyzing Regenxbio’s Valuation Metrics
Regenxbio (RGNX) generated revenues of $40.03 million in the second quarter compared to $6.56 million in Q2 2017.
Teva Stock Continues to Trend Higher on Positive News
Teva Pharmaceutical Industries (TEVA) has risen ~9% over the last five days.
FDA Approves Teva’s Generic Version of EpiPen, Stock Up 7.5%
Teva Pharmaceutical Industries (TEVA) received FDA approval for the generic version of Mylan’s (MYL) allergy products EpiPen and EpiPen Jr.
Why Vertex Is Expected to Report Robust EPS Growth in 2018
Wall Street analysts have projected Vertex Pharmaceuticals’ fiscal 2018 adjusted diluted EPS to be around $3.8, which would be a YoY rise of approximately 93.1%.
OPKO Health Expects Its Loss per Share to Shrink This Year
In the third quarter, OPKO Health (OPK) expects research and development expenses of $33 million–$38 million, and foresees its total operating expenses falling to $285 million–$305 million.
OPKO Health’s Q3 2018 Revenue Expectations
In the third quarter, OPKO Health (OPK) expects service revenue of $200 million–$220 million, assuming stable reimbursement rates and a small rise in volumes.
What Does Alnylam Pharmaceuticals’ Valuation Trend Indicate?
In August, of the 16 analysts covering Alnylam Pharmaceuticals, 13 have given the stock “buy” or higher ratings.
What Alnylam Pharmaceuticals’ Bottom Line Trend Indicates
Alnylam Pharmaceuticals’ interest income increased from $2.58 million in the second quarter of 2017 to $6.1 million in the second quarter of 2018.
Sarepta Therapeutics’ Q2 2018 Earnings and Revenue Growth
Sarepta Therapeutics (SRPT) released its Q2 2018 earnings on August 8, surpassing analysts’ estimates for EPS and revenues.
What’s Ionis Pharmaceuticals’ Valuation after Q2 Results?
Ionis Pharmaceuticals (IONS), a leading RNA-targeted therapeutics developing company, aims to develop best-in-class drugs for life-threatening diseases.
What to Expect from Sarepta’s Second-Quarter Earnings
Wall Street analysts estimate Sarepta’s revenues will increase by over 100% to $71.6 million in Q2 2018 as compared to revenues of $35.0 million during Q2 2017.
Why Tonix Pharmaceuticals Stock Soared Today
Today, Tonix Pharmaceuticals (TNXP) was trading at $4.23, which represents ~7.09% growth from yesterday’s close of $3.95.
Incyte’s Valuations on July 6
Incyte (INCY) posted revenues of $382.3 million in Q1 2018, a marginal decrease in YoY revenues compared to $384.1 million in Q1 2017.
How Ionis Pharmaceuticals’ Valuation Compares
Ionis Pharmaceuticals (IONS), a therapeutics development leader, commercializes products in collaboration with other pharmaceutical companies.
Analysts Are Mostly Positive on Exelixis in July
On July 3, Exelixis (EXEL) stock closed at $21.4, a ~15.7% increase from its 52-week low of $18.5 on May 10.
Pediatric Atopic Dermatitis Indication May Boost Dupixent Revenue
A label expansion could further advance Dupixent’s position in the atopic dermatitis market.
Regeneron Focuses on Expanding Eylea’s Diabetic Retinopathy Label
On March 19, Regeneron announced positive top line results from its Phase 3 PANORAMA trial.
Regeneron Is Expected to Witness a Modest Revenue Rise in 2018
Regeneron (REGN) currently has six FDA-approved drugs and 17 investigational therapies in its research pipeline.
Solid Biosciences’ Stock Price Rose 46.6% on June 19
On June 19, 2018, Solid Biosciences’ (SLDB) stock price rose ~46.6% to $43.00. On June 19, the stock price hit a 52-week high of $54.84.
The Economy Is on a Roll, and It’s Bringing the Stock Market Along With It
Jobs data released this morning shows that the U.S. economy is firing on all cylinders, and the stock market has responded by rallying.
A Look at Incyte’s Valuation as of May 25
Incyte reported EPS of -$0.19 on revenue of $382.3 million in Q1 2018 compared to revenue of $384.1 million in Q1 2017.
Ionis Pharmaceuticals’ Valuation on May 23
Ionis Pharmaceuticals (IONS), a leading therapeutics company, develops and markets drugs for life-threatening diseases.
Do Alnylam Pharmaceuticals’ Cash Flows Look Healthy?
Since the beginning of 2018, the stock price of Alnylam Pharmaceuticals has dropped from $130 levels to $100 as of May 21.
What Led to MEI Pharma Stock’s 55% Rise Last Week?
MEI Pharma (MEIP) saw a 55% rise in its stock price between May 11 and May 18.
How Did Regeneron’s Eylea, Kevzara, and Zaltrap Perform in 1Q18?
In 1Q18, Eylea generated net global revenue of $1.6 billion compared to $1.3 billion in 1Q17.
How Regeneron’s Praluent and Dupixent Performed in 1Q18
In 1Q18, Regeneron Pharmaceuticals’ (REGN) Praluent reported revenue of $60 million compared to $36 million in 1Q17.
Upadacitinib Could Drive AbbVie’s Long-Term Growth
In April 2018, AbbVie (ABBV) positive results for its Phase 3 SELECT-COMPARE trial, which evaluated the safety and efficacy of upadacitinib for adults with moderate-to-severe rheumatoid arthritis.
Exploring the Growth of Regeneron’s Praluent
In April 2017, the FDA approved a supplemental biologics license application (or sBLA) for Praluent for a once-monthly dose.
Why Did Regeneron Pharmaceuticals’ Stock Price Rise Last Week?
On March 28, 2018, Regeneron Pharmaceuticals (REGN) was trading at $344.36, a ~9.8% rise from its 52-week low of $313.53.
Regeneron Pharmaceuticals’ Dupixent, Kevzara, and Zaltrap
In 4Q17, Regeneron Pharmaceuticals’ (REGN) Dupixent generated revenues of $139.0 million compared to $88.9 million in 3Q17.
How Regeneron Pharmaceuticals’ Eylea Performed in 4Q17 and 2017
In 4Q17, Eylea generated net global revenues of $1.6 billion compared to ~$1.4 billion in 4Q16.
Why Regeneron Pharmaceuticals’ Stock Price Fell
Of the 27 analysts tracking Regeneron Pharmaceuticals (REGN) in March, five recommended a “strong buy” and six analysts recommended a “buy.”
How Novartis’s Ophthalmology Business Performed in 2017
In 4Q17, Novartis’s Ophthalmology business generated revenues of $1.35 billion, which reflected ~2% growth on a year-over-year (or YoY) basis and ~2% growth quarter-over-quarter.
How Ionis’s Spinraza Performed in 4Q17
Ionis Pharmaceuticals’ (IONS) Spinraza (nusinersen) is a drug designed for the treatment of spinal muscular atrophy.
How Did Ionis’s Revenues Trend in 4Q17?
Ionis (IONS) is a leading biopharmaceutical company focused on discovering, developing, and commercializing RNA-targeted therapies.
Novartis Plans to Launch RTH258 in 2019 to Treat nAMD
Novartis (NVS) plans to submit to an FDA application seeking regulatory approval for investigational drug RTH258.
Regeneron Pharmaceuticals and Its Financial Performance
Regeneron Pharmaceuticals (REGN) generated total revenues of $5.8 billion in fiscal 2017 compared with $4.8 billion in fiscal 2016.
A Look at Regeneron Pharmaceuticals’ Product Pipeline
Regeneron Pharmaceuticals (REGN) currently has 15 products in clinical development.
Regeneron Pharmaceuticals’ Kevzara, Arcalyst, and Zaltrap
In January 2017, Regeneron Pharmaceuticals’ (REGN) Kevzara was approved in Canada for the treatment of patients with active rheumatoid arthritis.
Repatha Could Significantly Drive Amgen’s Revenue Growth in 2018
In 1Q17, 2Q17, and 3Q17, Repatha generated revenues of $49.0 million, $83.0 million, and $89.0 million, respectively.
A Look at Ionis Pharmaceuticals’ January 2018 Valuation
On January 5, Ionis Pharmaceuticals’ stock value had risen ~4.3% over the last 12 months. Analysts expect the stock to rise ~14.0% over the next 12 months.
How’s Incyte’s Valuation in January 2018?
Analysts expect Incyte Corporation’s revenue to rise ~26.7% to $413.8 million in 4Q17 compared to $326.5 million in 4Q16.
Pfizer Expects Eucrisa to Report Sales of ~$2.0 Billion
Eucrisa growth trends On December 14, 2016, Pfizer (PFE) announced that it had secured FDA approval for its mild-to-moderate AD (atopic dermatitis) therapy, Eucrisa (crisaborole) 2% ointment, for patients over two years old. This drug was added to Pfizer’s portfolio through the acquisition of Anacor Pharmaceuticals, which was completed in June 2016 for ~$5.2 billion. […]
Regeneron’s Kevzara Approved for Treatment of Rheumatoid Arthritis
In May 2017, the US FDA (Food and Drug Administration) approved Regeneron Pharmaceuticals’ (REGN) and Sanofi’s (SNY) Kevzara (sarilumab) for the treatment individuals with moderate to severe rheumatoid arthritis.
Regeneron’s Dupixent Approved for Atopic Dermatitis
In March 2017, the US Food and Drug Administration (FDA) approved Sanofi’s (SNY) and Regeneron Pharmaceuticals’ (REGN) Dupixent (dupilumab) for the treatment of individuals with moderate-to-severe atopic dermatitis.
Analysts’ Recommendations for Regeneron
Dupilumab could be long-term growth driver In October 2017, Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that their Phase 3 dupilumab study had met its primary and secondary endpoints. The study was conducted to evaluate the safety and efficacy of dupilumab for the treatment of individuals with severe steroid-dependent asthma. In the study, at 24 weeks, when […]
Inside Novartis’s Ophthalmology Drugs Now
In 3Q17, Novartis’s (NVS) Lucentis generated revenues of ~$481 million, which was ~5% higher YoY (year-over-year) and 1% higher QoQ (quarter-over-quarter).
Inside Roche’s Lucentis, Activase, and Mircera in 3Q17
In 3Q17, Roche Holding’s (RHHBY) Lucentis generated revenues of 399 million Swiss francs, which reflected ~7% growth on a year-over-year (or YoY) basis.
Analyst Recommendations for Vertex Pharmaceuticals in October
After 3Q17, Vertex Pharmaceuticals (VRTX) increased its guidance for cystic fibrosis product revenues, from $1.87 billion–$2.1 billion to $2.10 billion–$2.15 billion.
Gilead Sciences on the Street: Analyst Recommendations in October
Of the 28 analysts tracking Gilead Sciences in October 2017, three have recommended a “strong buy,” while 11 have recommended a “buy.”
Inclisiran: Long-Term Growth Driver for The Medicines Company?
According to a Monte Carlo simulation performed at Harvard, it’s estimated that 5.0 million patients in the United States stand to benefit from PCSK9 inhibitor therapy.
Analysts’ Recommendations for The Medicines Company in October
In 2Q17, The Medicines Company (MDCO) reported revenues of $18.7 million, which is a fall of 66.0% on a YoY (year-over-year) basis.
Sanofi’s Kevzara Could Be Solid Addition to Rheumatoid Arthritis
Launched in US markets in June 2017, Kevzara (sarilumab), Sanofi (SNY) and Regeneron’s (REGN) IL-6 receptor antibody, has received favorable feedback from the physician community.
Dupixent May Be Strong Growth Driver for Sanofi in the Future
Regeneron (REGN) and Sanofi’s (SNY) Dupixent has seen stronger total prescription (or TRx) performance since its launch than Cosentyx, the dermatology biologic drug by Novartis (NVS).
Repatha Could Be Amgen’s Long-Term Growth Driver
In September 2017, Amgen presented new analysis from the cardiovascular outcomes study.
How Does Novartis’s Ophthalmology Portfolio Look?
In 1H17, Novartis’s (NVS) Travoprost drugs reported revenues of around $290 million, which is a ~6% decline on a YoY basis.
How Is Novartis’s Lucentis Positioned after 1H17?
In 1H17, Novartis’s (NVS) Lucentis reported revenues of around $922 million, which is a ~1% decline on a year-over-year (or YoY) basis.
The IBB Biotechnology ETF: The Drugs You Need?
The iShares NASDAQ Biotechnology ETF (IBB) aims to track the investment results of the NASDAQ Biotechnology Index, which comprises NASDAQ-listed biotechnology and pharmaceuticals companies.
Kevzara May Emerge as a Prominent Rheumatoid Arthritis Drug in 2017
Regeneron and Sanofi have submitted an application seeking regulatory approval for Kevzara in Japan.
Label Expansion in Asthma Indication May Boost Dupixent’s Sales
Dupixent combined with standard of care also showed 12%–15% improvement in FEV1 from baseline in asthma patients after 12 weeks of treatment compared to those treated with standard of care alone.
Regulatory Approval in Asthma Indication May Boost Dupixent’s Sales
In June 2017 and July 2017, healthcare providers wrote prescriptions for Regeneron (REGN) and Sanofi’s (SNY) Dupixent for 750 new patients on a weekly basis.
Eylea Leads the Retinal Diseases Sector
In 1H17, Eylea’s total sales rose 10% on a year-over-year basis.
Regeneron Is Focused on Increasing Awareness for Eylea in 2017
Regeneron is currently studying the drug in combination with nesvacumab, an antibody to angiopoietin 2, in two Phase 2 trials, in wet AMD and diabetic macular edema indications.
Analysts’ Recommendations for Regeneron in September 2017
Of the 26 analysts covering Regeneron Pharmaceuticals in September 2017, seven rated the stock a “strong buy,” six rated it as a “buy,” and 12 rated it as a “hold.” One analyst rated the company as a “strong sell.”
Dupixent and Kevzara: Regeneron’s Long-Term Growth Drivers?
In 2Q17, Regeneron Pharmaceuticals’ (REGN) Dupixent generated revenues of $28.6 million.
Analyst Recommendations for Regeneron Pharmaceuticals in August
Twenty-five analysts were analyzing Regeneron Pharmaceuticals in August 2017. Seven of them recommended a “strong buy,” and five recommended a “buy.”
What’s Ionis Pharmaceuticals’ Valuation?
Ionis Pharmaceuticals (IONS) has been one of the leading pharmaceutical companies in the RNA-targeted therapeutic space for over 26 years.
What Amgen’s Analysts Recommend in August 2017
Of the 24 analysts covering Amgen, four have recommended a “strong buy” for the stock, while six have recommended a “buy.”
Analysts’ Recommendations for Regeneron in July 2017
In May 2017, Regeneron Pharmaceuticals (REGN) and Inovio Pharmaceuticals (INO) entered into an agreement for an immuno-oncology clinical study.
Dupixent Could Substantially Drive Regeneron’s Growth
In March 2017, the FDA approved Regeneron and Sanofi’s Dupixent injection for the treatment of adult individuals with moderate to severe atopic dermatitis.
Kevzara Launch Could Boost Regeneron’s Revenue Growth
The FDA’s approval of Regeneron Pharmaceuticals’ Kevzara was based on the pivotal Phase 3 MOBILITY and TARGET clinical trials.
Praluent Could Witness Steady Growth in 2017
In 2016, Regeneron Pharmaceuticals’ Praluent reported revenue of ~$116.3 million, compared to $10.5 million in 2015.
Eylea Could Continue to Generate High Revenue
Regeneron Pharmaceuticals (REGN) markets Eylea in the United States, and Bayer (BAYZF) commercializes the drug outside the US market.
What Drove Biogen Stock in 2Q17?
Biogen (BIIB) stock has risen ~0.40% in 2Q17 and ~4.1% year-to-date as of July 7, 2017.
The Rise of Amgen Stock in 2Q17
Amgen (AMGN) stock has risen ~5.8% in 2Q17, while it has risen ~17.4% year-to-date as of July 7, 2017.